New eye drops aim to soothe dry eyes in major trial

NCT ID NCT06717152

Symptom relief Sponsor: Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tested SJP-0132 eye drops against placebo in 427 Chinese adults with dry eye disease. Participants used the drops four times daily for 8 weeks. The goal was to see if the drops improve eye surface damage and reduce dryness symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: SJP-0132 eye drops
What this could lead to: If successful, SJP-0132 could offer a new treatment option to relieve dry eye symptoms and improve eye surface health.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The benefit over placebo may be modest, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

427 people

The number who actually took part.

Started

Dec 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged between 18 and 70 at the time of the informed consent * Outpatient patients * The patient's self-described dry eye symptom is more than 6 months or has the clinical diagnosis certificate of dry eye in the past 6 months at the time of the informed consent * Tear film break-up time of \<= 5 seconds at the beginning of screening and treatment period Exclusion Criteria: * Patients who have previously used SJP-0132 eye drops * Patients who participated in or are currently participating in or planned to participate in other clinical studies within three months prior to the start of the screening period * Patients who plan to wear corneal contact lenses between the beginning of the screening period and the end of the treatment period * Patients who have undergone eye surgery (including laser surgery) or planned to undergo any eye surgery during the study period within one year prior to the beginning of the corneal transplantation surgery or screening period * Any ophthalmic disease except for the dry eye (including eyeball or periocular infection, allergic or proliferative eye disease) is present at the beginning of the screening period and at the beginning of the treatment period. However, it does not include chronic eye disease patients who do not need treatment and may not become worse before the end of the treatment period * Have known history of hypersensitivity or serious adverse reaction to any of the study drug ingredients * Patients suffering from serious cardiovascular, respiratory, endocrine, digestive, urinary, blood, neurological, mental, ocular or peripheral malignancies (cured in or at the beginning of the screening period but not exceeding five years), at the beginning of screening and treatment period * A patient at the beginning of screening and at treatment period who has a positive blood serum pregnancy test result or is in lactation, or a female patient who has planned pregnancy during the study period or has fertility but is unable to use effective contraception during the study period, or a female partner of a male patient who is unable to use effective contraception during the study * Patients identified at the beginning of screening and treatment period as researchers, research coordinators, researchers and immediate relatives of the persons referred to above * At the beginning of the screening and treatment period, investigators determine that patients who were unable to comply with the requirements of the program or were unable to come to hospital on schedule (e.g. patients who planned to travel or stay in the field during the period prior to the end of the treatment period) * At the beginning of the screening and treatment period, investigators decide that the patients who were not suitable for the trial were not suitable for the other reasons * Meet the other protocol-specified exclusion criteria

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye

Contacts and locations

Locations

Affiliated Eye Hospital of Nanchang University

Nanchang, Jiangxi, China
Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China
Beijing Hospital

Beijing, Beijing Municipality, China
Beijing Tongren Hospital

Beijing, Beijing Municipality, China
Dalian No.3 People's Hospital

Dalian, Liaoning, China
Eye & ENT Hospital of Fudan University

Shanghai, Shanghai Municipality, China
Eye Hospital, WMU

Wenzhou, Zhejiang, China
Henan Eye Hospital

Zhengzhou, Henan, China
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong

Shantou, Guangdong, China
Longhua Hospital Shanghai University of Traditional Chinese Medicine

Shanghai, Shanghai Municipality, China
Ningbo Eye Hospital

Ningbo, Zhejiang, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, China
Peking University Shenzhen Hospital

Shenzhen, Guangdong, China
People's Hospital of Hunan Province

Changsha, Hunan, China
Renmin Hospital of Wuhan University

Wuhan, Hubei, China
Shandong Eye Hospital

Jinan, Shandong, China
Shanxi Eye Hospital

Taiyuan, Shanxi, China
Shenzhen People's Hospital

Shenzhen, Guangdong, China
The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, China
The First Affiliated Hospital of University of South China

Hengyang, Hunan, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China
The First Bethune Hospital of Jilin University

Changchun, Jilin, China
The Fourth Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China
The Fourth People's Hospital of Shenyang

Shenyang, Liaoning, China
The Second Norman Bethune Hospital of Jilin University

Changchun, Jilin, China
The first people's hospital of Xian Yang

Xianyang, Shanxi, China
Tianjin Medical University Ophthalmology Hospital

Tianjin, Tianjin Municipality, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China
West China Hospital of Sichuan University

Chengdu, Sichuan, China
Xiamen Eye Center of Xiamen University

Xiamen, Fujian, China
Xiangya Hospital Central South University

Changsha, Hunan, China
Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China
Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.